Pacific Biosciences of California, Inc.
PACB
$1.32
$0.043.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.02% | 5.04% | 3.89% | -10.72% | -17.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.02% | 5.04% | 3.89% | -10.72% | -17.35% |
| Cost of Revenue | -0.61% | -3.11% | 6.15% | -11.92% | -15.70% |
| Gross Profit | 8.94% | 29.83% | -1.90% | -7.75% | -21.38% |
| SG&A Expenses | -25.40% | -27.80% | -24.40% | -8.86% | -1.63% |
| Depreciation & Amortization | -98.93% | -98.95% | 1,248.35% | 1,269.69% | 1,674.80% |
| Other Operating Expenses | -17.92% | -30.71% | 314.33% | 14.79% | 14.79% |
| Total Operating Expenses | -56.61% | -58.29% | 56.55% | 56.26% | 53.16% |
| Operating Income | 71.14% | 72.74% | -82.18% | -93.27% | -94.23% |
| Income Before Tax | 75.19% | 80.57% | -76.41% | -27.41% | -27.80% |
| Income Tax Expenses | 1,587.76% | 5,642.86% | 0.63% | 160.17% | 100.43% |
| Earnings from Continuing Operations | 75.04% | 80.45% | -76.34% | -27.75% | -31.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.04% | 80.45% | -76.34% | -27.75% | -31.46% |
| EBIT | 71.14% | 72.74% | -82.18% | -93.27% | -94.23% |
| EBITDA | 28.40% | 36.65% | 29.53% | 20.13% | 19.40% |
| EPS Basic | 75.90% | 81.33% | -60.91% | -16.29% | -19.63% |
| Normalized Basic EPS | 72.89% | 74.91% | -67.78% | -79.58% | -79.60% |
| EPS Diluted | 75.61% | 81.10% | -61.12% | -16.39% | -19.47% |
| Normalized Diluted EPS | 72.57% | 74.64% | -71.51% | -77.41% | -77.52% |
| Average Basic Shares Outstanding | 5.75% | 7.43% | 9.28% | 9.14% | 8.35% |
| Average Diluted Shares Outstanding | 3.60% | 5.19% | 6.95% | 11.35% | 10.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |